• Daniel F. Zimmerman advises public and private companies, private equity funds and other investors on securities regulation matters, mergers and acquisitions, tender offers and exchange offers, securities offerings, corporate finance, corporate governance, and restructurings. He represents public and private buyers and sellers in a variety of negotiated and contested domestic and cross-border acquisitions, securities offerings, restructurings and other financings. Daniel’s experience includes contested proxy solicitations and hostile acquisition proposals, activist matters from both the activist and defensive perspectives, and complex debt restructurings in and out of court. His work regularly encompasses both domestic U.S. and cross-border transactions.

    Dan previously served in the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC). Prior to joining Kramer Levin, he worked in private practice at other global law firms.

    Experience

    • Represented multiple public companies in mergers and acquisitions transactions subject to the proxy and tender offer rules, including going-private transactions and de-SPAC business combinations for both sponsors and operating companies.

    • Represented public companies in connection with multiple underwritten and Rule 144A offerings of convertible, high-yield and investment-grade notes.

    • Represented noteholders of a public company in connection with its Chapter 11 bankruptcy and post-emergence governance and financing matters, including stock exchange listing matters and Rule 144A notes offerings and redemption of outstanding senior secured first lien notes.

    • Regularly representing noteholders in connection with financial restructuring proposals to distressed companies, and related corporate, financing and securities law matters, including U.S. securities law matters relating to cross-border restructurings.

    • Assisted an Ireland-based pharmaceutical company in connection with its successful defense of a hostile tender offer by an investment fund, its $8.6 billion acquisition by a U.S. drugmaker and a Rule 144A offering of $850 million in aggregate principal amount of senior notes.

    • Counseled a soft drink company in the acquisition of its North American bottling operations and the simultaneous split-off of its European business as well as its acquisition of the company's bottling operations in Norway and Sweden, with a total transaction value of approximately $12.5 billion.

    • Advised a Bermuda-based insurer and reinsurer in its successful unsolicited offer to buy a competing reinsurer for $1.65 billion.

    Credentials

    Education

    • J.D., Columbia Law School, 2001
      • Harlan Fiske Stone Scholar
      • Articles Editor, Columbia Business Law Review
    • M.B.A., Columbia University, 2001
    • B.Eng., Vanderbilt University, 1994

    Bar Admissions

    • New York, 2002